bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.91 USD
-0.03 (-3.48%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $0.92 +0.01 (0.60%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
bluebird bio, Inc. [BLUE]
Reports for Purchase
Showing records 481 - 500 ( 532 total )
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
A potential Cure for SCD May Not be Far Fetched, Target to $120
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Compelling, But Non-Curative Treatment Option From Competitor
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Gene Therapy Pushing the Envelope, Re-Defining Healthcare, Target to $90
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Updated Data Further Validates LentiGlobin in Beta-Thal, Positive Signal Observed in First SCD Patient, Reiterate OUTPERFORM and Raising PT to $94
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Q3:14 Financial Update, Data from Three Beta-Thalassemia Northstar Study Patients to be Presented at ASH, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
bluebird bio''s Partners at the Baylor College of Medicine to Present Data on Novel T Cell Therapy Approaches at ASH 2014, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Partners at the Baylor College of Medicine to Present Data on Novel T Cell Therapy Approaches at ASH 2014
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Look at Beta-Thal Patient in Northstar Study
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Judgment Calls Based on a Single Patient''s Data Are Hazardous
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Look at Beta-Thal Patient in Northstar Study; Likely on Similar Track to Transfusion Independence, Despite Single Unit Transfusion, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.